Acer Therapeutics received approval from the FDA for its new drug application, or NDA, for Olpruva for oral suspension, according to a letter posted to the agency’s site. Reference Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ACER: